Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
Journal of Comparative Effectiveness Research · 2023-09 · 12 (9)
DOI: 10.57264/cer-2023-0066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2023-09. Verfasst von Aaron T Gerds und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44106, USA. Hauptthemen laut MEDLINE: Polycythemia Vera. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
Patients with polycythemia vera (PV), a rare and chronic blood cancer, are at a higher risk for thromboembolic events, progression to myelofibrosis, and leukemic transformation. In 2021, ropeginterferon alfa-2b-njft (BESREMi ® ) was approved in the US to treat adults with PV. The purpose of this study is to estimate the cost–effectiveness of ropeginterferon alfa-2b-njft, used as a first- or second-line treatment, for the treatment of patients with PV in the US. Materials & methods: A Markov cohort model was developed from the healthcare system perspective in the United States. Model inputs were informed by the PROUD-PV and CONTINUATION-PV studies and published literature. The model population included both low-risk and high-risk patients with PV. The model compared ropeginterferon alfa-2b-njft used either as first- or second-line versus an alternative treatment pathway of first-line hydroxyurea followed by ruxolitinib.
Results
Over the modeled lifetime, ropeginterferon alfa-2b-njft provided an additional 0.4 higher quality-adjusted life years (QALYs) and 0.4 life-years with an added cost of USD60,175, resulting in a cost per QALY of USD141,783. The model was sensitive to treatment costs, the percentage of patients who discontinue hydroxyurea, the percentage of ropeginterferon alfa-2b-njft users who switch to monthly dosing, the percentage of ropeginterferon alfa-2b-njft users as 2nd line treatment, and the treatment response rates. A younger patient age at baseline and a higher percentage of patients with low-risk disease improved the cost–effectiveness of ropeginterferon alfa-2b-njft.
Conclusion
Ropeginterferon alfa-2b-njft is a cost-effective treatment option for a broad range of patients with PV, including both low- and high-risk patients and patients with and without prior cytoreductive treatment with hydroxyurea.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44106, USA.
- PharmaEssentia USA Corporation, Burlington, MA 01803, USA.
- Stratevi LLC, Boston, MA 02111, USA.
ORCID-Profile: Aaron T Gerds, Alexandra G Ellis
Zitieren
APA
Gerds, A. T., Castro, C., Snopek, F., Flynn, M. M., Ellis, A. G., Manning, M., & Urbanski, R. (2023). Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera. Journal of Comparative Effectiveness Research, 12(9). https://doi.org/10.57264/cer-2023-0066
Vancouver
Gerds AT, Castro C, Snopek F, Flynn MM, Ellis AG, Manning M, et al. Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera. Journal of Comparative Effectiveness Research. 2023;12(9). doi:10.57264/cer-2023-0066
BibTeX
@article{Gerds2023,
author = {Gerds, Aaron T and Castro, Claudia and Snopek, Frank and Flynn, Megan M and Ellis, Alexandra G and Manning, Meredith and Urbanski, Ray},
title = {Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera},
journal = {Journal of Comparative Effectiveness Research},
year = {2023},
volume = {12},
number = {9},
doi = {10.57264/cer-2023-0066}
}
EUVIMED